ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CURX
TCRT (36) ENSC (30) MBRX (34) SNGX (42) ⌘ Pro Terminal →

Curanex Pharmaceuticals Inc (CURX) — RQD Stock Rating Cockpit

$5.85 +13.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.98

Curanex Pharmaceuticals Inc (CURX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $8.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CURX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CURX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Curanex Pharmaceuticals Inc (NASDAQ: CURX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $5.85 (+13.37% 1D, market cap $8.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CURX compare to TCRT and ENSC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CURX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M) and ENSC (Ensysce Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $8.2M). Among the 5-stock peer group, CURX leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CURX?
▼

Per CURX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002025942), Curanex Pharmaceuticals Inc generated $11.9M in revenue (+1061.2% YoY), -$4.2M in net income, and -$10.5M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.98 (+2.22%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (5)Whales (9)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$14 Bull$5 Base$4 Bear
📬 FREE CURX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CURX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY CURX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$4.88-2.5% Next Q
Q2 (-2Q)
32
Grade E$4.76+0% Next Q
Q3 (-1Q)
34
Grade E$4.76+22.9% Next Q
Current
37
Grade D-$5.85-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CURX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CURX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.74) and Max Pain ($6.14) forces dealer call-delta covering toward $14.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CURX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CURX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
55.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE22% OF RANGE
L: $4$5.85H: $14
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on CURX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CURX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CURX)

  • ✓Walkthrough of CURX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CURX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.00%⚡ TESTING RESISTANCE
2026-11-03O $4.94H $5.85L $4.94C $5.85VOL 9.3K
RES: $6.15SUP: $4.00SMA50: $4.74SMA200: $6.15
$22.21$17.16$12.11$7.06$2.01RES $6.15SUP $4.00$5.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CURX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CURX Butterfly Map → + Track CURX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +1061.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CURX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CURX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CURX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CURX)

Health Care Rank #551 of 1015 ⚔️ TCRT vs CURX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CURX vs. TCRT, ENSC, MBRX, SNGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Curanex Pharmaceuticals Inc (CURX) ranks #551 by composite RQD confidence (37/100, grade D-) and #909 by equity capitalization ($8.1M). Within this direct 5-issuer industry benchmark cohort, CURX leads on earnings valuation at N/A trailing P/E, while CURX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SNGX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with CURX at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CURX ACTIVE
Curanex Pharmaceuticals Inc
D- 37/100 — — -35.0% +13.37% $8.1M Benchmark Subject
TCRT
Alaunos Therapeutics Inc.
D- 36/100 — — -35.0% -10.26% $8.1M /tcrt-vs-curx →
ENSC
Ensysce Biosciences Inc.
E 30/100 — — -35.0% -9.24% $8.2M /ensc-vs-curx →
MBRX
Moleculin Biotech Inc.
E 34/100 — — -35.0% +5.32% $8.3M /mbrx-vs-curx →
SNGX
Soligenix Inc.
D- 42/100 — — -35.0% +1.49% $7.7M /sngx-vs-curx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002025942 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Curanex Pharmaceuticals Inc (CURX) reported GAAP revenue of $11.9M (+1061.2% vs. FY2024 revenue of $1.0M ) , GAAP net income of -$4.2M, operating cash flow of -$10.5M, and free cash flow of -$10.5M (-1787.1% YoY). On the balance sheet, CURX closed FY2025 with $11.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $11.9M -$4.2M -$10.5M -$10.5M $11.6M —
FY2024 (FY) 2024-12-31 $1.0M -$361.5K -$555.6K -$555.6K $517.9K —

3. CURX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CURX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Curanex Pharmaceuticals Inc (NASDAQ: CURX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $5.85 (+13.37% 1D, market cap $8.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does CURX compare to TCRT and ENSC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CURX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M) and ENSC (Ensysce Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $8.2M). Among the 5-stock peer group, CURX leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CURX?

Per CURX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002025942), Curanex Pharmaceuticals Inc generated $11.9M in revenue (+1061.2% YoY), -$4.2M in net income, and -$10.5M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CURX trading relative to its 50-day, 200-day, and 52-week technical levels?

CURX last traded at $5.85 (+13.37% on volume of 3,357 shares), positioning the stock +23.42% above its 50-day simple moving average ($4.74) and -4.88% below its 200-day simple moving average ($6.15). Across its 52-week range of $3.58 to $13.80, CURX sits at the 22.2% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.12 to $6.58).

Direct Sub-Reports: CURX RQD Cockpit CURX 12M Forecast CURX Earnings & Move CURX Dividends & DRIP CURX Insiders & 13F CURX Whale Options CURX Profit Sankey CURX News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CURX — Curanex Pharmaceuticals Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Curanex Pharmaceuticals Inc (CURX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $5.85 (+13.37% 1D, market capitalization $8.1M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Curanex Pharmaceuticals Inc (CURX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Curanex Pharmaceuticals Inc (CURX) reported $11.9M in annual revenue (up from $1.0M in FY2024, +1061.2% YoY) and -$4.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($1.0M revenue, -$361.5K net income) through FY2025, CURX scaled operating cash flow to -$10.5M and free cash flow to -$10.5M, backed by $11.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $3.58 – $13.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only cross-market linkage in the data is the liquidity beta described above, which implies CURX may respond to changes in net liquidity conditions more than typical equities. Investors should monitor whether any such liquidity sensitivity persists given the weak r value, and should note that with a $7.7M market cap and 0% FCF yield, the company's capacity to absorb adverse financing conditions is not established by the source data.

  • Key Question #1: Can CURX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $11.9M and free cash flow of -$10.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CURX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CURX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Curanex Pharmaceuticals Inc (CURX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CURX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CURX Bull vs. Bear Conversation Board — What's Your Call at $5.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CURX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CURX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $6.09 (+18.0%)
📌 Pinned Debate

The Butterfly liquidity signal assigns a BULLISH 5.70x Net Liquidity beta with a MACRO TAILWIND SCORE of 96/100, though its r = -0.24 c

Here is why I am bullish on CURX here at $5.16: The Butterfly liquidity signal assigns a BULLISH 5.70x Net Liquidity beta with a MACRO TAILWIND SCORE of 96/100, though its r = -0.24 correlation is weak.. Compare CURX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.90 are getting bought.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $4.18 (-19.0%)
Spot @ $5.16

CURX scores 34/100 (grade E) with -35% ROIC, 0% FCF yield, -$10.5M FY 2025 free cash flow, and Piotroski F-Score 1/9.

Careful chasing CURX at $5.16. CURX scores 34/100 (grade E) with -35% ROIC, 0% FCF yield, -$10.5M FY 2025 free cash flow, and Piotroski F-Score 1/9.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.18 on multiple compression.

LIVE TAPE